Compare Hims and Hers Health Inc (HIMS) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Millicom International Cellular S.A. Common Stock — how do they compare? Hims and Hers Health Inc trades at $26.88 (market cap $6.47B), while Millicom International Cellular S.A. Common Stock trades at $80.51 (market cap $13.49B). The key difference: Millicom International Cellular S.A. Common Stock is far larger — about 2.1× Hims and Hers Health Inc's market cap, and Millicom International Cellular S.A. Common Stock pays a 3.73% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| HIMS | TIGO | |
|---|---|---|
Market Cap | $6.47B | $13.49B |
Volume | 10,989,212 | 1,314,537 |
Sector | Health | Media |
52-Week High | $62.76 | $104.31 |
52-Week Low | $14.52 | $45.81 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $7.17B | $24.53B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.71, down 3.04% on the day, amid a securities class action lawsuit. Technical indicators show a bullish trend, with support near $29 and resistance at $32. Fundamentally, the company reported $2.35B in 2025 revenue but swung to a net loss of -$142M in 2026, with a negative net margin of -5.51%. Valuation ratios are elevated, with a P/E of 57.14 and EV/EBITDA of 205.86. Analyst consensus is a 'Hold' with a $32.17 price target, while recent news is dominated by legal actions.
The outlook for HIMS is clouded by legal overhangs and profitability challenges despite top-line growth. Investment opportunity hinges on resolving litigation and returning to profitability, but risks include regulatory scrutiny and execution missteps. The stock's high valuation multiples require strong future earnings to justify, making it speculative in the near term.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →
